With growing bipartisan support for feasible measures to control skyrocketing prescription medication costs, a Health Affairs Blog post published today describes four proposals to strengthen and modernize cost control measures that already exist in the United States.
Dear Majority Leader McConnell, Minority Leader Schumer, Speaker Ryan, and Democratic Leader Pelosi: We the undersigned urge Congress to reject devastating funding cuts to the National Institutes of Health (NIH) proposed under the President’s Fiscal Year (FY) 2018 “skinny budget,” released on March 16, 2017. Of grave concern is the targeted elimination of the Fogarty International Center at NIH. This indiscriminate cut jeopardizes life-saving research required to end devastating global diseases like tuberculosis (TB) and HIV/AIDS, as well as malaria, dengue, and Ebola.
March 20, 2017 – Mark Harrington, TAG's executive director, included in his keynote speech at the Critical Path to TB Drug Regimens meeting the importance of public and private sector funding for research, of thoughtful regulatory strategies, and of rapid uptake of…
In advance of World TB Day, Treatment Action Group (TAG), Health GAP, AIDS-Free World and Treatment Action Campaign (TAC) urge G20 member states to commit by the July 7, 2017 G20 summit to increase annual funding contributions to USD $1.17 billion for research and development (R&D) to set us on the path to end tuberculosis (TB).
March 2017--Tuberculosis (TB) is the leading infectious cause of death, and drug-resistant forms of TB account for one in three deaths from antimicrobial resistance. TB research has received scant resources, limiting the possibility of developing the new diagnostic, treatment, and prevention…
TAG strongly opposses the President’s 2018 budget blueprint, which threatens research essential to ending the epidemics of HIV/AIDS, tuberculosis (TB), and hepatitis C virus (HCV) in the United States and globally by cutting funding and eliminating programs.
February 8, 2017: TAG and partner organizations advocating for the rights of people affected by HIV and TB around the world encouraged the President’s Emergency Plan for AIDS Relief (PEPFAR) to support the immediate introduction of the LAM test in all PEPFAR-funded…
Public health groups welcomed today’s announcement by Johns Hopkins University (JHU) and the Medicines Patent Pool (MPP) of an agreement that could expedite the research and development of a promising tuberculosis drug and lead to improved treatment options for people living with TB.
TAG's annual review of progress we've made on the the fight to end HIV/AIDS, Viral Hepatitis, and Tuberculosis.
On November 16, 2016, TAG held a community webinar on advocacy for TB R&D funding. This webinar builds upon TAG's annual Report on Tuberculosis Research Funding Trends to begin discussion on next steps for TB R&D funding advocacy into 2017…